RecruitingPhase 2NCT07197866

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Sponsor

Teva Branded Pharmaceutical Products R&D LLC

Enrollment

200 participants

Start Date

Sep 30, 2025

Study Type

INTERVENTIONAL

Conditions

Multiple System Atrophy

Summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Eligibility

Min Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TEV-56286 for people with multiple system atrophy. The study is currently recruiting participants at 30 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTEV-56286

administered orally

Locations(34)

Teva Investigational Site 15554

La Jolla, California, United States

Teva Investigational Site 15544

Boca Raton, Florida, United States

Teva Investigational Site 15555

Tampa, Florida, United States

Teva Investigational Site 15546

Kansas City, Kansas, United States

Teva Investigational Site 15549

New York, New York, United States

Teva Investigational Site 15551

New York, New York, United States

Teva Investigational Site 15548

Pittsburgh, Pennsylvania, United States

Teva Investigational Site 15543

Spokane, Washington, United States

Teva Investigational Site 35290

Bordeaux, France

Teva Investigational Site 35291

Paris, France

Teva Investigational Site 35292

Toulouse, France

Teva Investigational Site 32818

Dresden, Germany

Teva Investigational Site 32822

Düsseldorf, Germany

Teva Investigational Site 32825

Kassel, Germany

Teva Investigational Site 32824

Marburg, Germany

Teva Investigational Site 32820

München, Germany

Teva Investigational Site 32819

Münster, Germany

Teva Investigational Site 80203

Haifa, Israel

Teva Investigational Site 80204

Tel Aviv, Israel

Teva Investigational Site 30299

Bologna, Italy

Teva Investigational Site 30297

Catania, Italy

Teva Investigational Site 30298

Milan, Italy

Teva Investigational Site 30296

Roma, Italy

Teva Investigational Site 30295

Salerno, Italy

Teva Investigational Site 84137

Niigata, Japan

Teva Investigational Site 84138

Sagamihara, Japan

Teva Investigational Site 84141

Sanda-shi, Japan

Teva Investigational Site 84135

Sendai, Japan

Teva Investigational Site 31324

Barcelona, Spain

Teva Investigational Site 31323

Barcelona, Spain

Teva Investigational Site 31321

Barcelona, Spain

Teva Investigational Site 31320

Pamplona, Spain

Teva Investigational Site 31322

Seville, Spain

Teva Investigational Site 31319

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07197866

Related Trials

Expansion Study of ALT001 in Patients With Multiple System Atrophy

NCT07476352

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

NCT07805967

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

NCT065967461 location

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

NCT066833651 location

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT0656823761 locations